Literature DB >> 24197279

Venous thromboembolism after major cancer surgery: temporal trends and patterns of care.

Vincent Q Trinh1, Pierre I Karakiewicz1, Jesse Sammon2, Maxine Sun1, Shyam Sukumar2, Mai-Kim Gervais3, Shahrokh F Shariat4, Zhe Tian1, Simon P Kim5, Keith J Kowalczyk6, Jim C Hu7, Mani Menon2, Quoc-Dien Trinh8.   

Abstract

IMPORTANCE: There is limited data on the prevalence and mortality of venous thromboembolism (VTE) following oncologic surgery.
OBJECTIVE: To evaluate the trends, factors, and mortality of VTE following major cancer surgery. DESIGN, SETTING, AND PARTICIPANTS: Patients undergoing colectomy, cystectomy, esophagectomy, gastrectomy, hysterectomy, lung resection, pancreatectomy, or prostatectomy were identified retrospectively using the Nationwide Inpatient Sample between January 1, 1999, and December 30, 2009, resulting in a weighted estimate of 2,508,916 patients. MAIN OUTCOMES AND MEASURES: Venous thromboembolism following major cancer surgery was assessed according to date, patient, and hospital characteristics. The determinants of in-hospital VTE were evaluated using logistic regression analysis.
RESULTS: Venous thromboembolism showed an estimated annual percentage increase of 4.0% (95% CI, 2.9% to 5.1%), which contrasts with a 2.4% (95% CI, -4.3% to -0.5%) annual decrease in mortality in VTE after major cancer surgery. In multivariate logistic regression analysis, older age (odds ratio [OR], 1.03; P < .001), female sex (OR, 1.25; P < .001), black race (vs white; OR, 1.56; P < .001), Charlson comorbidity index score of 3 or more (OR, 1.85; P < .001), and Medicaid (vs private insurance; OR, 2.04; P < .001), Medicare (OR, 1.39; P < .001), and uninsured (OR, 1.49; P < .001) status were associated with an increased risk of VTE. Conversely, other (nonwhite and nonblack) race (OR, 0.75; P < .001) was associated with a lower risk of VTE. Among hospital characteristics, urban location (OR, 1.32; P < .001) and teaching status (OR, 1.08; P = .01) were associated with greater odds of VTE. Patients with vs without VTE experienced 5.3-fold greater odds of mortality. CONCLUSIONS AND RELEVANCE: During our study period, VTE events following major cancer surgery increased in frequency; however, associated VTE mortality decreased. Changing VTE detection guidelines and better management of this condition may explain our findings.

Entities:  

Mesh:

Year:  2014        PMID: 24197279     DOI: 10.1001/jamasurg.2013.3172

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  39 in total

1.  Venous thromboembolism events after thoracic surgery: global steps toward prevention.

Authors:  Robert M Van Haren; Virginia R Litle
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Towards a precision medicine in venous thromboembolism associated to lung cancer.

Authors:  Luis Jara-Palomares; Teresa Elias-Hernandez; Maria Isabel Asensio-Cruz; Samira Marin-Romero; Remedios Otero-Candelera
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 3.  The Society for Translational Medicine: the assessment and prevention of venous thromboembolism after lung cancer surgery.

Authors:  Hui Li; Gening Jiang; Servet Bölükbas; Chun Chen; Haiquan Chen; Keneng Chen; Jun Chen; Xiangli Cui; Wentao Fang; Shugeng Gao; Sebastien Gilbert; Jianhua Fu; Xiangning Fu; Yasuhiro Hida; Shanqing Li; Xiaofei Li; Yin Li; Hecheng Li; Yongjun Li; Deruo Liu; Lunxu Liu; Jianxing He; Jie He; Giuseppe Marulli; Hiroyuki Oizumi; Marc de Perrot; René Horsleben Petersen; Yaron Shargall; Alan Sihoe; Qunyou Tan; Qun Wang; Shun Xu; Mei Yang; Yuanhua Yang; Zhentao Yu; Lanjun Zhang; Xun Zhang; Heng Zhao; Xiuyi Zhi
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Association of the Risk of a Venous Thromboembolic Event in Emergency vs Elective General Surgery.

Authors:  Samuel W Ross; Kali M Kuhlenschmidt; John C Kubasiak; Lindsey E Mossler; Luis R Taveras; Thomas H Shoultz; Herbert A Phelan; Caroline E Reinke; Michael W Cripps
Journal:  JAMA Surg       Date:  2020-06-01       Impact factor: 14.766

5.  Cardiovascular Outcomes of Patients With Pulmonary Hypertension Undergoing Noncardiac Surgery.

Authors:  Nathaniel R Smilowitz; Andrew Armanious; Sripal Bangalore; Harish Ramakrishna; Jeffrey S Berger
Journal:  Am J Cardiol       Date:  2019-02-08       Impact factor: 2.778

6.  Hypercoagulability After Resection of Thoracic Malignancy: A Prospective Evaluation.

Authors:  Michelle B Mulder; Kenneth G Proctor; Evan J Valle; Alan S Livingstone; Dao M Nguyen; Robert M Van Haren
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

7.  Comprehensive analysis of in-hospital delirium after major surgical oncology procedures: A population-based study.

Authors:  Marco Bandini; Michele Marchioni; Felix Preisser; Sebastiano Nazzani; Zhe Tian; Markus Graefen; Francesco Montorsi; Fred Saad; Shahrokh F Shariat; Luigi Schips; Alberto Briganti; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2019-09-27       Impact factor: 1.862

8.  Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.

Authors:  Aditya Bagrodia; Ranjit Sukhu; Andrew G Winer; Eric Levy; Michael Vacchio; Byron Lee; Eugene J Pietzak; Timothy F Donahue; Eugene Cha; Gopa Iyer; Daniel D Sjoberg; Andrew J Vickers; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Bernard H Bochner
Journal:  Clin Genitourin Cancer       Date:  2017-08-10       Impact factor: 2.872

9.  Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial.

Authors:  Jie-Qiong Song; Li-Zhen Xuan; Wei Wu; Jun-Feng Huang; Ming Zhong
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

10.  Insurance Type and Major Complications After Hysterectomy.

Authors:  Carolyn Weaver Swenson; Neil S Kamdar; Helen Levy; Darrell A Campbell; Daniel M Morgan
Journal:  Female Pelvic Med Reconstr Surg       Date:  2017 Jan/Feb       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.